Region VIII Research Center for Excellence for Biodefen*

描述（由申请人提供）： 该提案的目的是在美国PHS第八区建立一个生物防御和新兴传染病研究区域卓越中心（RCE）。RCE的目标是：1）制定以研究者为指导的研究计划，以解决涉及NIH A-C类优先病原体的研究和转化需求，2）培训研究人员和其他人员进行生物防御和新兴传染病活动和职业，3）开发关键的科学核心设施，以支持RCE和NIH的研究和培训活动，4）开发转化研究能力，以测试和验证疫苗，治疗，和诊断NIH优先病原体，和5）提供关键的激增能力，包括设施和训练有素的人员，为区域和国家生物防御或新出现的疾病紧急情况。 第八区RCE将由大学、联邦机构和公司组成，为生物防御研究和培训提供高度互动的多学科环境。RCE将为NIH优先病原体开发关键知识，技术，试剂，疫苗和治疗方法，并将提供人力资源和设施能力，以解决潜在BT病原体和相关因子的有目的释放或自然出现。RCE将在参与机构中组织成一系列相互关联的研究和培训中心， 各自的能力和使命。该联盟将强调NIH A-C类人畜共患病病原体的研究和产品开发，其中许多病原体的研究不如其他NIH优先病原体，包括土拉弗朗西斯菌，伯克霍尔德菌属，鼠疫耶尔森氏菌，柯克斯体属，和虫媒病毒性脑炎（东方马脑炎病毒、西方马脑炎病毒、西尼罗河病毒和长曲棍球病毒），以及其它虫媒病毒和啮齿动物传播的A-C类病原体。RCE联合体和新的区域VIII生物防护实验室，以及动物模型，产品开发和制造，基因组学/蛋白质组学和选择代理档案核心将提供卓越的能力， 确定新产品，提供新信息，并将这些发现转化为可用于生物防御的产品。拟议的第八区研究和培训项目将提供新的诊断方法、治疗方法和疫苗，以及新的科学家、临床医生和公共卫生从业人员队伍，以帮助应对新出现的疾病，无论这些疾病是由有目的的还是自然事件造成的。第八区域区域环境评估和区域边界线将为生物防御研究和应对提供区域和国家资源。

DESCRIPTION (provided by applicant): The purpose of this proposal is to establish a Regional Center of Excellence (RCE) for Biodefense and Emerging Infectious Diseases Research in U.S. PHS Region VIII. The RCE goals are to: 1) develop investigator-directed research programs to address research and translational needs involving NIH Category A-C priority pathogens, 2) train researchers and other personnel for biodefense and emerging infectious disease activities and careers, 3) develop critical scientific core facilities to support research and training activities of the RCE and NIH, 4) develop translational research capacity for testing and validating vaccines, therapeutics, and diagnostics for NIH priority pathogens, and 5) provide critical surge capacity, including facilities and trained personnel, for regional and national biodefense or emerging disease emergencies. The Region VIII RCE will be comprised of a consortium of universities, federal agencies, and companies, which will provide a highly interactive, multi-disciplinary environment for biodefense research and training. The RCE will develop critical knowledge, technologies, reagents, vaccines, and therapeutics for NIH priority pathogens and will provide human resource and facility capacity to address the purposeful release or natural emergence of potential BT pathogens and related agents. The RCE will be organized as a series of interconnected research and training nodes at participating institutions, which will complement and enhance their respective abilities and missions. The consortium will emphasize research and product development for NIH Category A-C zoonotic pathogens, many of which are less well studied than other NIH priority pathogens, including Francisella tularensis, Burkholderia spp, Yers/n/a pestis, Coxiella spp., and arboviral encephalitides (Eastern equine encephalitis, Western equine encephalitis virus, West Nile, and LaCrosse viruses), and other arboviral and rodent-borne Category A-C pathogens. The RCE consortium combined and the new Region VIII Biocontainment Laboratory, with the Animal Models, Product Development and Manufacturing, Genomics/Proteomics, and Select Agent Archive Cores will provide exceptional capacity to identify new products and provide new information and to translate these discoveries to usable products for biodefense. The proposed Region VIII research and training projects will provide new diagnostics, therapeutics, and vaccines as well as a new cadre of scientist, clinicians, and public health practitioners to help address emerging diseases, whether resulting from purposeful or natural events. The Region VIII RCE and RBL will provide a regional and national resource for biodefense research and response.